Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 9, 537
eCollection

Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma

Affiliations
Review

Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma

Dana L Casey et al. Front Oncol.

Abstract

Ewing sarcoma (ES) family of tumors includes bone and soft tissue tumors that are often characterized by a specific translocation between chromosome 11 and 22, resulting in the EWS-FLI1 fusion gene. With the advent of multi-modality treatment including cytotoxic chemotherapy, surgery, and radiation therapy, the prognosis for patients with ES has substantially improved. However, a therapeutic plateau is now reached for both localized and metastatic disease over the last two decades. Burdened by the toxicity limits associated with the current frontline systemic therapy, there is an urgent need for novel targeted therapeutic strategies. In this review, we discuss the current treatment paradigm of ES, and explore preclinical evidence and emerging treatments directed at tumor signaling pathways and immune targets.

Keywords: Ewing sarcoma; antibodies; immunotherapy; pediatric sarcomas; targeted therapy.

Figures

Figure 1
Figure 1
Overview of current molecularly targeted therapy for Ewing sarcoma. For STEAP1 and CD99, antibodies have been tested in mouse models of Ewing sarcoma but not in the clinical trial setting. Cer, ceramide.
Figure 2
Figure 2
Clinical trial results of anti-IGF-1R therapy across phase II trials.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

References

    1. Esiashvili N, Goodman M, Marcus RB. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol. (2008) 30:425–30. 10.1097/MPH.0b013e31816e22f3 - DOI - PubMed
    1. Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene. (2001) 20:5747–54. 10.1038/sj.onc.1204598 - DOI - PubMed
    1. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, et al. . Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA. (1993) 90:5752–6. 10.1073/pnas.90.12.5752 - DOI - PMC - PubMed
    1. Toretsky JA, Connell Y, Neckers L, Bhat NK. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol. (1997) 31:9–16. 10.1023/A:1005716926800 - DOI - PubMed
    1. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest. (1997) 99:239–47. 10.1172/JCI119152 - DOI - PMC - PubMed

LinkOut - more resources

Feedback